SEC Form 4
Vertex Pharmaceuticals Inc (VRTX) insider trading
In the 12 months to Oct 23, 2026, 13 VRTX insiders reported open-market sales of $158.1M across 52 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $158.1M
- 52 filings · 13 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 52 of 52
- All $158.1M sold was pre-arranged
Who traded VRTX, and when
- Sale
- Sale, pre-arranged (10b5-1)
VRTX daily close from Oct 23, 2025 to Oct 23, 2026, between $409.47 and $557.96, last $523.93. 52 sale and 0 purchase filings by 13 insiders, marked at their filing dates. Jeffrey M. Leiden, Executive Chairman: sold $60.9M across 2 filings, first filed Nov 17, 2025, last Dec 5, 2025. Amit Sachdev, EVP Chief Patient & Ext Af Off: sold $28.4M across 2 filings, first filed Feb 23, 2026, last Feb 26, 2026. Reshma Kewalramani, CEO & President: sold $19.7M across 1 filing, first filed Mar 3, 2026, last Mar 3, 2026. Carmen Bozic, EVP and CMO: sold $11.3M across 10 filings, first filed Mar 3, 2026, last Jun 30, 2026. Charles F. Wagner Jr., EVP, CO & FO: sold $10.8M across 2 filings, first filed Dec 5, 2025, last Jan 8, 2026. Ourania Tatsis, EVP, Chief Reg. & Quality Off.: sold $6.5M across 7 filings, first filed Dec 5, 2025, last Jul 7, 2026. 7 others: sold $20.4M across 28 filings, first filed Nov 19, 2025, last Jul 7, 2026.
Largest mark · tap a row for others
Jeffrey M. Leiden · Executive Chairman
Sale $32,292,320
73,292 shares at $440.60 avg
Filed Nov 17, 2025 · traded Nov 13
Pre-arranged (10b5-1) · close on filing date $434.02
Jeffrey M. Leiden · Executive Chairman
Executive Chairman
$60.9M soldAmit Sachdev · EVP Chief Patient & Ext Af Off
EVP Chief Patient & Ext Af Off
$28.4M soldReshma Kewalramani · CEO & President
CEO & President
$19.7M soldCarmen Bozic · EVP and CMO
EVP and CMO
$11.3M soldCharles F. Wagner Jr. · EVP, CO & FO
EVP, CO & FO
$10.8M soldOurania Tatsis · EVP, Chief Reg. & Quality Off.
EVP, Chief Reg. & Quality Off.
$6.5M sold7 others
Combined, one mark per week
$20.4M soldHas Vertex Pharmaceuticals Inc's CEO sold stock?
Yes. Reshma Kewalramani (CEO) sold 40,000 shares ($19.7M) in Mar 2026, all under a pre-arranged 10b5-1 plan.
Open-market trades
52 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Jeffrey M. Leiden | Executive Chairman | $60.9M | — | 2 | 100% of sales | |
| Amit Sachdev | EVP Chief Patient & Ext Af Off | $28.4M | — | 2 | 100% of sales | |
| Reshma Kewalramani | CEO & President | $19.7M | — | 1 | 100% of sales | |
| Carmen Bozic | EVP and CMO | $11.3M | — | 10 | 100% of sales | |
| Charles F. Wagner Jr. | EVP, CO & FO | $10.8M | — | 2 | 100% of sales | |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | $6.5M | — | 7 | 100% of sales | |
| Duncan McKechnie | EVP, Chief Commercial Officer | $5.7M | — | 4 | 100% of sales | |
| Jonathan Biller | EVP and Chief Legal Officer | $3.8M | — | 5 | 100% of sales | |
| Edward Morrow Atkinson III | EVP, Chief Technical Ops. Off. | $3.6M | — | 4 | 100% of sales | |
| Mark E. Bunnage | EVP, Chief Scientific Officer | $3.0M | — | 4 | 100% of sales | |
| Joy Liu | EVP and Chief Legal Officer | $2.1M | — | 5 | 100% of sales | |
| Kristen Ambrose | SVP & Chief Accounting Officer | $2.0M | — | 4 | 100% of sales | |
| Sangeeta N. Bhatia | Director | $267.7K | — | 2 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Duncan McKechnie EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 1,541 | $519.00 | $799.8K | 11,001 | |
traded | Ourania Tatsis EVP, Chief Reg. & Quality Off. | SalePre-arranged (10b5-1) | 1,500 | $524.99 | $787.5K | 45,321 | |
traded | Joy Liu EVP and Chief Legal Officer | SalePre-arranged (10b5-1) | 828 | $502.71 | $416.2K | 19,131 | |
traded | Carmen Bozic EVP and CMO | SalePre-arranged (10b5-1) | 596 | $482.50 | $287.6K | 15,337 | |
traded | Carmen Bozic EVP and CMO | SalePre-arranged (10b5-1) | 1,020 | $462.17 | $471.4K | 15,933 | |
traded | Carmen Bozic EVP and CMO | SalePre-arranged (10b5-1) | 4,062 | $450.00 | $1.8M | 16,953 | |
traded | Carmen Bozic EVP and CMO | SalePre-arranged (10b5-1) | 1,745 | $450.00 | $785.3K | 21,015 | |
traded | Joy Liu EVP and Chief Legal Officer | SalePre-arranged (10b5-1) | 828 | $439.91 | $364.2K | 19,959 | |
traded | Carmen Bozic EVP and CMO | SalePre-arranged (10b5-1) | 1,974 | $450.00 | $888.3K | 22,760 | |
traded | Carmen Bozic EVP and CMO | SalePre-arranged (10b5-1) | 1,354 | $453.45 | $614.0K | 24,734 | |
traded | Mark E. Bunnage EVP, Chief Scientific Officer | SalePre-arranged (10b5-1) | 33 | $453.45 | $15.0K | 7,284 | |
traded | Carmen Bozic EVP and CMO | SalePre-arranged (10b5-1) | 6,988 | $450.00 | $3.1M | 26,088 | |
traded | Sangeeta N. Bhatia Director | SalePre-arranged (10b5-1) | 318 | $423.73 | $134.7K | 4,924 | |
traded | Joy Liu EVP and Chief Legal Officer | SalePre-arranged (10b5-1) | 1,104 | $425.02 | $469.2K | 20,729 | |
traded | Joy Liu EVP and Chief Legal Officer | SalePre-arranged (10b5-1) | 978 | $449.17 | $439.3K | 21,833 | |
traded | Carmen Bozic EVP and CMO | SalePre-arranged (10b5-1) | 2,329 | $450.95 | $1.1M | 33,076 | |
traded | Carmen Bozic EVP and CMO | SalePre-arranged (10b5-1) | 2,329 | $481.79 | $1.1M | 35,405 | |
traded | Duncan McKechnie EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 2,633 | $498.42 | $1.3M | 12,489 | |
traded | Duncan McKechnie EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 2,437 | $475.30 | $1.2M | 15,122 | |
traded | Joy Liu EVP and Chief Legal Officer | SalePre-arranged (10b5-1) | 892 | $495.96 | $442.4K | 22,811 | |
traded | Carmen Bozic EVP and CMO | SalePre-arranged (10b5-1) | 2,329 | $480.31 | $1.1M | 37,734 | |
traded | Reshma Kewalramani CEO & President | SalePre-arranged (10b5-1) | 40,000 | $493.47 | $19.7M | 128,545 | |
traded | Kristen Ambrose SVP & Chief Accounting Officer | SalePre-arranged (10b5-1) | 357 | $483.36 | $172.6K | 6,624 | |
traded | Kristen Ambrose SVP & Chief Accounting Officer | SalePre-arranged (10b5-1) | 223 | $486.35 | $108.5K | 6,981 | |
traded | Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | SalePre-arranged (10b5-1) | 668 | $486.35 | $324.9K | 18,432 | |
traded | Jonathan Biller EVP and Chief Legal Officer | SalePre-arranged (10b5-1) | 945 | $486.35 | $459.6K | 13,659 | |
traded | Mark E. Bunnage EVP, Chief Scientific Officer | SalePre-arranged (10b5-1) | 620 | $486.35 | $301.5K | 7,284 | |
traded | Duncan McKechnie EVP, Chief Commercial Officer | SalePre-arranged (10b5-1) | 4,910 | $487.65 | $2.4M | 19,969 | |
traded | Amit Sachdev EVP Chief Patient & Ext Af Off | SalePre-arranged (10b5-1) | 1,846 | $486.35 | $897.8K | 55,570 | |
traded | Ourania Tatsis EVP, Chief Reg. & Quality Off. | SalePre-arranged (10b5-1) | 260 | $486.35 | $126.5K | 46,763 | |
traded | Amit Sachdev EVP Chief Patient & Ext Af Off | SalePre-arranged (10b5-1) | 58,613 | $468.83 | $27.5M | 58,934 | |
traded | Kristen Ambrose SVP & Chief Accounting Officer | SalePre-arranged (10b5-1) | 2,195 | $484.87 | $1.1M | 7,750 | |
traded | Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | SalePre-arranged (10b5-1) | 2,848 | $484.93 | $1.4M | 20,727 | |
traded | Jonathan Biller EVP and Chief Legal Officer | SalePre-arranged (10b5-1) | 3,720 | $484.18 | $1.8M | 15,748 | |
traded | Mark E. Bunnage EVP, Chief Scientific Officer | SalePre-arranged (10b5-1) | 3,619 | $484.31 | $1.8M | 8,486 | |
traded | Ourania Tatsis EVP, Chief Reg. & Quality Off. | SalePre-arranged (10b5-1) | 977 | $483.52 | $472.4K | 48,650 | |
traded | Sangeeta N. Bhatia Director | SalePre-arranged (10b5-1) | 266 | $500.00 | $133.0K | 4,299 | |
traded | Jonathan Biller EVP and Chief Legal Officer | SalePre-arranged (10b5-1) | 988 | $499.00 | $493.0K | 16,838 | |
traded | Ourania Tatsis EVP, Chief Reg. & Quality Off. | SalePre-arranged (10b5-1) | 1,500 | $499.99 | $750.0K | 46,132 | |
traded | Kristen Ambrose SVP & Chief Accounting Officer | SalePre-arranged (10b5-1) | 1,376 | $460.43 | $633.6K | 10,127 | |
traded | Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | SalePre-arranged (10b5-1) | 1,751 | $460.43 | $806.2K | 22,046 | |
traded | Jonathan Biller EVP and Chief Legal Officer | SalePre-arranged (10b5-1) | 1,925 | $460.43 | $886.3K | 20,819 | |
traded | Mark E. Bunnage EVP, Chief Scientific Officer | SalePre-arranged (10b5-1) | 2,021 | $460.43 | $930.5K | 12,914 | |
traded | Ourania Tatsis EVP, Chief Reg. & Quality Off. | SalePre-arranged (10b5-1) | 466 | $460.43 | $214.6K | 51,436 | |
traded | Ourania Tatsis EVP, Chief Reg. & Quality Off. | SalePre-arranged (10b5-1) | 4,500 | $474.99 | $2.1M | 42,293 | |
traded | Charles F. Wagner Jr. EVP, CO & FO | SalePre-arranged (10b5-1) | 9,532 | $461.00 | $4.4M | 37,725 | |
traded | Jonathan Biller EVP and Chief Legal Officer | SalePre-arranged (10b5-1) | 347 | $449.00 | $155.8K | 15,306 | |
traded | Jeffrey M. Leiden Executive Chairman | SalePre-arranged (10b5-1) | 63,781 | $449.20 | $28.7M | 82,018 | |
traded | Ourania Tatsis EVP, Chief Reg. & Quality Off. | SalePre-arranged (10b5-1) | 4,500 | $449.99 | $2.0M | 46,793 | |
traded | Charles F. Wagner Jr. EVP, CO & FO | SalePre-arranged (10b5-1) | 14,000 | $456.00 | $6.4M | 44,725 | |
traded | Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | SalePre-arranged (10b5-1) | 2,500 | $434.58 | $1.1M | 16,852 | |
traded | Jeffrey M. Leiden Executive Chairman | SalePre-arranged (10b5-1) | 73,292 | $440.60 | $32.3M | 24,066 |
GET /stocks/filings/vX/form-4?tickers=VRTX&filing_date.gte=2025-10-23&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"VRTX"
],
"issuer_cik": "0000875320",
"owner_cik": "0001789815",
"accession_number": "0000875320-26-000245",
"form_type": "4",
"filing_date": "2026-07-07",
"period_of_report": "2026-07-02",
"issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
"issuer_trading_symbol": "VRTX",
"owner_name": "Tatsis Ourania",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "EVP, Chief Reg. & Quality Off.",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-07-02",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 1500,
"transaction_price_per_share": 524.99,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 45321,
"transaction_value": 787485,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025."
}
]
},
{
"tickers": [
"VRTX"
],
"issuer_cik": "0000875320",
"owner_cik": "0002062139",
"accession_number": "0000875320-26-000243",
"form_type": "4",
"filing_date": "2026-07-07",
"period_of_report": "2026-07-02",
"issuer_name": "VERTEX PHARMACEUTICALS INC / MA",
"issuer_trading_symbol": "VRTX",
"owner_name": "McKechnie Duncan",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "EVP, Chief Commercial Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-07-02",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 1541,
"transaction_price_per_share": 519,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 11001,
"transaction_value": 799779,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 98 records
- Option exercises8 records
- Tax withholding42 records
- Grants and awards42 records
- Gifts2 records
- Other4 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
Build this yourself
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for VRTX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.